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A B S T R A C T
Apolipoprotein E (APOE) is a multifunctional protein synthesized and secreted by multiple mammalian tissues.
Although hepatocytes contribute about 75% of the peripheral pool, APOE can also be expressed in adipose tissue,
the kidney, and the adrenal glands, among other tissues. High levels of APOE production also occur in the brain,
where it is primarily synthesized by glia, and peripheral and brain APOE pools are thought to be distinct. In
humans, APOE is polymorphic, with three major alleles (ε2, ε3, and ε4). These allelic forms dramatically alter
APOE structure and function. Historically, the vast majority of research on APOE has centered on the important
role it plays in modulating risk for cardiovascular disease and Alzheimer's disease. However, the established
effects of this pleiotropic protein extend well beyond these two critical health challenges, with demonstrated
roles across a wide spectrum of biological conditions, including adipose tissue function and obesity, metabolic
syndrome and diabetes, fertility and longevity, and immune function.
While the spectrum of biological systems in which APOE plays a role seems implausibly wide at first glance,
there are some potential unifying mechanisms that could tie these seemingly disparate disorders together. In the
current review, we aim to concisely summarize a wide breadth of APOE-associated pathologies and to analyze
the influence of APOE in the development of several distinct disorders in order to provide insight into potential
shared mechanisms implied in these various pathophysiological processes.
1. Introduction
Apolipoprotein E (APOE) was first identified in humans as a con-
stituent of very low-density lipoproteins (VLDL) in 1973 by Shore and
Shore (1973). Initially termed “arginine-rich apoprotein”, Utermann
named the protein apolipoprotein E in 1975 (Utermann, 1975), dis-
tinguishing it from others in the growing class of apolipoproteins. It was
later found in triglyceride-rich lipoproteins, both in animal and human
models, after being induced by cholesterol supplementation (Mahley
et al., 1975; Shore et al., 1974).
In humans, the APOE gene is located on the long arm of chromo-
some 19 (locus 19q13.2). It consists of four exons and three introns,
with a length of 3597 nucleotides (Das et al., 1985). The polymorphic
nature of APOE was first discovered by Utermann (Utermann et al.,
1977) and later clarified by Zanis and Breslow (Zannis et al., 1981).
Thus, the human gene presents three common alleles: ε2, ε3 and ε4. The
combination of these three alleles produces six genotypes (Table 1). The
resulting proteins differ only by one or two amino acids at positions 112
and 158. APOE2 has a cysteine at both positions, APOE3 has a cysteine
at 112 and an arginine at 158, and APOE4 has an arginine at both
positions (Weisgraber, 1994). It is hypothesized that these residues
influence the properties of the isoforms by altering the domain inter-
action between the N and C terminal domains (Mahley and Huang,
2012) which are presumably translated into a change in protein func-
tion. The most common isoform is APOE3, being found in the 70–80%
of modern populations, whereas APOE4 is found in 10–15% and APOE2
in 5–10% of the population (Corbo and Scacchi, 1999). Although other
mammals express APOE, this allelic variation is only found in humans.
The ε4 is considered as the ancestral human allele, with the ε2 (E2) and
ε3 (E3) alleles arising only after the divergence of the human and
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primate lineages (Hanlon and Rubinsztein, 1995). Sequence analysis
reveals that the primary structure of the primate APOE is identical to
human APOE4 (Hanlon and Rubinsztein, 1995), although with a ter-
tiary structure more similar to APOE3, which results in binding pre-
ferences that are functionally similar to human APOE3 (McIntosh et al.,
2012).
Historically, the vast majority of research on APOE has centered on
the important role it plays in modulating risk for cardiovascular disease
(CVD) and late onset Alzheimer's disease (AD). However, the estab-
lished effects of this pleiotropic protein extend well beyond these two
critical health challenges, with demonstrated roles for APOE across a
wide spectrum of biological conditions, including adipose tissue func-
tion and obesity, metabolic syndrome and diabetes, fertility and long-
evity, immune function, and infectious diseases.
In the current review, we aim to concisely summarize a wide
breadth of APOE-associated pathologies and to analyze the influence of
APOE in the development of several distinct disorders in order to pro-
vide insight into potential shared mechanisms implied in these various
pathophysiological processes.
2. Functions of APOE in the brain and periphery
APOE is a multifunctional protein synthesized and secreted by
multiple mammalian tissues. Hepatocytes contribute about 75% of the
peripheral pool of APOE. In addition, APOE can also be expressed in
adipose tissue, the kidney, and the adrenal glands, among other tissues
(Huang and Mahley, 2014). High levels of APOE production also occur
in the brain (Huang and Mahley, 2014). While brain and peripheral
pools of APOE are distinct, secreted APOE shares similar systemic
functions in each of these locations of synthesis, primarily regulating
lipoprotein metabolism and supporting cellular differentiated function
(Huang and Mahley, 2014).
2.1. Lipid transport and metabolism
APOE is involved in lipid transport through its association with
chylomicron remnants, VLDL, and high-density lipoproteins (HDL)
(Mahley et al., 1979a, 1979b; Shore and Shore, 1973; Utermann, 1975).
APOE interacts with large heparan sulfate proteoglycans (HSPGs) on
the hepatocyte surface and promotes internalization of the lipoprotein
particles via lipoprotein receptors of the LDL receptor family (Fig. 1)
(Mahley et al., 1979a, 1979b). APOE genotype influences plasma and
brain cholesterol levels (Chernick et al., 2019; Sing and Davignon,
1985). Plasma LDL cholesterol levels are both associated with the three
APOE isoforms in the order of APOE4>APOE3>APOE2. This asso-
ciation is counterintuitive as APOE4 binds to LDL receptor with a
slightly higher affinity than APOE3, while APOE2 binds to the receptor
with much reduced affinity (Knouff et al., 1999).
Upon receptor-mediated endocytosis, APOE-containing lipoproteins
are processed in peripheral endosomes. In human hepatoma cells and
fibroblasts, lipids are targeted to the lysosomal compartment, while
APOE is found in peripheral recycling endosomes to be reutilized by the
cell (Heeren et al., 1999). Early studies in macrophages and hepatocytes
showed that APOE degradation only occurred within lysosomes,
whereas others have shown degradation in both lysosomal and
proteasomal compartments [reviewed in (Maaike et al., 2008; Wenner
et al., 2001)]. Secreted APOE can be re-uptaken into hepatocytes before
being released into the circulation and then re-secreted, but less so in
the case of APOE4 with consequent accumulation of cholesterol in the
cell (Heeren et al., 2004). Of note, astrocytes preferentially degrade
APOE4, leading to reduced APOE4 secretion and ultimately to reduced
brain APOE levels (Riddell et al., 2008).
2.2. Liver
The liver is the major site of lipoprotein uptake and APOE is a cri-
tical ligand for the clearance of these molecules. Within the liver, he-
patocytes and Kupffer cells both secrete APOE, with hepatocytes being
the major source of APOE in plasma (Getz and Reardon, 2009). It has
been proposed that VLDL particles in APOE4 individuals are enriched
with APOE4 on the surface, leading to accelerated liver uptake. As a
result, receptors are negatively regulated and LDL plasma levels in-
crease (Gregg et al., 1986; Li et al., 2013; Weintraub et al., 1987). As a
potential alternative mechanism, our group found that the high affinity
of APOE4 to the LDLR enhanced VLDL sequestration on the hepatocyte
surface but delayed their internalization (Altenburg et al., 2008).
Conversely, the marked reduction of APOE2 in its LDL receptor binding
activity translates into a low hepatic uptake of VLDL (Weisgraber,
1994): and as a consequence, APOE2 individuals display low LDL le-
vels. In addition, this isoform not only has a lower capacity to promote
lipolysis mediated by hepatic lipase (HL), but high APOE2 protein le-
vels also inhibit lipase-mediated lipolysis (LPL) by displacing its co-
factor apoC-II; concurrently, a lower processing of VLDL toward LDL
has been reported (Mahley et al., 1999).
2.3. Brain
APOE is the major apolipoprotein in the central nervous system
(CNS). In the brain, most cholesterol synthesis occurs in astrocytes
which are also the main producers of APOE under normal physiological
conditions (Fernandez et al., 2019). Upon activation microglia can
dramatically upregulate APOE expression and other cell types, such as
oligodendrocytes and neurons, have been also shown to produce APOE
under certain conditions (Fernandez et al., 2019). It is worth noting that
lipoprotein-borne APOE in the cerebrospinal fluid (CSF) is similar in
size and density to peripheral HDL (LaDu et al., 1998).
The APOE isoforms also differ in promoting cholesterol efflux.
APOE4 in the CSF associates with smaller APOE lipoproteins, pro-
moting less efficient cholesterol efflux than APOE3, whereas APOE2 has
the greatest cholesterol efflux efficiency. In addition to lipid home-
ostasis, APOE isoforms can differentially regulate multiple pathways
involved in neural development, as well as plasticity and neuronal re-
pair (Fernandez et al., 2019).
2.4. Adipose tissue
After the liver and brain, adipose tissue is a third major producer of
APOE (Zechner et al., 1991), which regulates the size of adipocytes,
triglyceride efflux, and the expression of genes related to fatty acid
oxidation (Huang et al., 2006). This endogenous expression of APOE in
adipocytes is modulated by regulators of insulin sensitivity, including
the liver X receptor (LXR), peroxisome proliferator-activated receptor
gamma (PPARγ), angiotensin II, inflammatory cytokines, as well as
nutritional status (Espiritu and Mazzone, 2008; Huang et al., 2007; Rao
et al., 2007; Yue and Mazzone, 2009). Endogenous adipocyte APOE
levels decrease in response to obesity, tumor necrosis factor-α (TNFα)
and angiotensin II, whereas PPARγ agonists, fasting and weight loss
increase its levels (Huang et al., 2007; Yue et al., 2004). Together, these
studies may suggest that APOE protects against nutritional changes,
preserving energy balance and adipose tissue functionality through its
roles in lipid acquisition (Huang et al., 2007).
Table 1
APOE genotypes.
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Triglyceride (TG) storage is one of the key functions of the adipose
tissue and adipocytes lacking APOE expression display impaired ac-
quisition of lipids from circulating VLDL through at least two separate
pathways. First, APOE knockout adipocytes internalize less VLDL
through the endocytic pathway due to reduced expression of LDL re-
ceptor family proteins (Huang et al., 2009). Second, lipoprotein lipase-
dependent accumulation of TG is also impaired in APOE knockout
adipocytes due to reduced transport of fatty acids across the adipocyte
membrane, likely due to reduced expression of caveolin-1 and plasma
membrane rafts (Huang et al., 2009). The APOE2 isoform also modifies
adipose tissue (Huang et al., 2015). “Targeted replacement” mice ubi-
quitously expressing human APOE2 in place of the endogenous mouse
APOE gene are hyperlipidemic, presenting with larger adipocytes and
gonadal fat pads compared to APOE3 mice (Arbones-Mainar et al.,
2008). Similar to ApoE knockout mice, adipocytes from mice expressing
APOE2 show decreased fatty acid uptake and decreased TG synthesis,
likely owing to the observation that newly synthesized APOE2 is more
rapidly degraded and less frequently secreted in these cells (Huang
et al., 2015, 2011).
2.5. Endothelium
The vascular endothelium is an interface between circulating blood
and the vessel wall. The activation of endothelial cells may result in the
recruitment of circulating monocytes and accumulation of monocyte-
derived macrophages (Mestas and Ley, 2008). Although endothelial
cells themselves do not appear to synthesize APOE, endothelium-re-
sident macrophages contribute to plasma APOE levels, releasing APOE
at atherosclerotic lesion sites (Linton and Fazio, 1999). This locally
secreted APOE inhibits the expression of the vascular cell adhesion
molecule 1 (VCAM-1), which is involved in the recruitment of mono-
cytes (Stannard et al., 2001). As a consequence, endothelial activation
is suppressed and monocyte-endothelial adhesion is attenuated. This
suppression likely occurs via stimulation of nitric oxide synthase (NOS),
as the nitric oxide inhibitor ethyl-isothiourea blocked this effect. Al-
ternatively, macrophage-derived APOE may also increase NO
production by disrupting the inhibitory interaction of endothelial NOS
with caveolin-1 (Yue et al., 2012). Therefore, APOE influences the in-
flammatory response by suppressing endothelial activation and the
expression of adhesion molecules.
Interestingly, the effect of APOE on the endothelium is isoform-
dependent. APOE3 binds to the ApoER2 receptor to stimulate en-
dothelial NOS and endothelial cell migration, attenuating monocyte-
endothelial adhesion. On the other hand, APOE4 does not stimulate
endothelial NOS and rather antagonizes APOE3/ApoER2 actions,
leading to a loss of the reparative and anti-inflammatory capacity of the
endothelium (Ulrich et al., 2014).
2.6. Female reproductive system
APOE is expressed in different tissues of the ovary, such as the en-
dometrium or granulosa cells. Several studies conducted with en-
dometrial biopsies have reported increased APOE levels during the lu-
teal phase of the menstrual cycle (Germeyer et al., 2013; Sundqvist
et al., 2012). However, in vitro studies have failed to reproduce the
progesterone effects on APOE levels (Germeyer et al., 2013). In the case
of granulosa cells, APOE expression has been seen to be regulated by
human chorionic gonadotropin (Beckmann et al., 1991). In addition,
the expression of APOE by granulosa cells may account for the differ-
ences in APOE concentration between the follicular fluid and the
plasma (Beckmann et al., 1991). It has also been reported that APOE
levels in follicular fluid fall dramatically when the follicle approaches
ovulation (Brown et al., 1989) while they increase with age, a fact that
has been associated with a smaller number of mature oocytes in elderly
women (Von Wald et al., 2010).
Rat studies have also found high levels of APOE expression in theca
and interstitial cells of follicles in animals at all stages of the estrous
cycle (Nicosia et al., 1992). Lower concentrations of APOE can stimu-
late theca cell androgen production (Zerbinatti and Dyer, 1999). In
contrast, at higher concentrations APOE selectively inhibits androgen
production without suppressing the production of progesterone
(Zerbinatti and Dyer, 1999). A possible explanation for this
Fig. 1. Clearance of lipoproteins is a multi-step process in which lipoproteins firstly bind to HSPGs followed by their uptaked by members of the LDL receptor family.
a) APOE lipoprotein receptors. Low density lipoprotein receptor (LDLR), widely expressed in hepatocytes; Very low density lipoproteins receptor (VLDLR), widely
expressed in adipose tissue, endothelium, skeletal muscle and heart; Apolipoprotein E receptor 2 or Low-density lipoprotein receptor-related protein 8 (ApoER2/
LRP8), mainly expressed in brain, testis and placenta; Low density lipoprotein receptor-related protein 1 (LRP1), ubiquitously expressed and key receptor for
maintaining cholesterol homeostasis. These receptors are characterized by a single transmembrane domain, a cytoplasmic tail with at least one NPxY motif, epi-
dermal grow factor (EGF) and b-propeller domains, and one or more ligand binding domains. b) Lipoproteins (CR, HDL, VLDL) are composed by a core containing
triglycerides and cholesterol (esterified and free) surrounded by phospholipids and APOE. c) Heparan sulfate proteoglycans (HSPGs) are glycoproteins containing one
or more covalently linked heparan sulfate chains. Some syndecans also contain a chondroitin sulfate chain.
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phenomenon is that intraovarian APOE induces theca and interstitial
cell apoptosis thereby controlling the production of androgen by those
cells (Zerbinatti and Dyer, 1999).
3. Primary APOE-associated diseases and conditions
3.1. Atherosclerosis and cardiovascular disease
Atherosclerosis is a progressive disease characterized by the accu-
mulation of lipids and fibrous elements in large arteries causing im-
paired endothelial function. It ranges from primary arterial atheroma
(inflammation and accumulation of macrophages loaded with choles-
terol in the artery wall) to the formation of plaques and inflammation of
the arterial wall, with the consequent risk of suffering thrombosis
(Fuster et al., 1992).
Atherosclerosis is the major cause of cardiovascular disease (CVD)
and APOE is abundant in atherosclerotic lesions, where it is secreted by
resident macrophages. This APOE production is atheroprotective, since
it contributes to reverse cholesterol transport, inhibits the proliferation
of smooth muscle cells, prevents lipid oxidation, and restricts platelet
aggregation (Linton and Fazio, 1999; Reddick et al., 1994). It has been
reported that APOE absence or dysfunction results in hyperlipidemia
and atherosclerotic lesions, while APOE injection or hepatic over-
expression protects (Plump et al., 1992; Stannard et al., 2001; Zhang
et al., 1992). Similarly, APOE4 carriers have higher levels of non-HDL
lipoproteins due mainly to reduced VLDL plasma clearance, which in
turn contributes to an increased risk if atherosclerosis and CVD
(Dallongeville et al., 1992; Knouff et al., 1999). This reduced clearance
of VLDL-borne APOE4 can be explained as a downregulation of the
LDLR or an enhanced VLDL sequestration on the hepatocyte, as de-
scribed above in the liver section.
Interestingly, mouse models have shown dysfunctional APOE4
macrophages that have problems phagocytosing apoptotic cells and are
more sensitive to cell death induced by oxidized LDL and lipopoly-
saccharide (LPS) (Altenburg et al., 2007). These phenomena produce
hyperinsulinemia due to the inflammation of adipose tissue in mice fed
a westernized diet (Cash et al., 2012), even in the absence of obesity. In
addition, APOE4 increases endoplasmic reticulum stress in macro-
phages, leading to mitochondrial malfunction that also contributes to
inflammation (Vats et al., 2006). As a consequence, and combined with
an ε4-associated increase in fasting LDL levels, risk of CVD and ather-
osclerosis may be increased.
3.2. Dyslipidemia
Although extremely rare, humans with APOE deficiency present
elevated VLDL and intermediate density lipoproteins (IDL) in plasma
(Schaefer et al., 1986). On the other hand, type III hyperlipoprotei-
nemia (HLP), characterized by the accumulation of chylomicron and
VLDL remnants is consistenly associated with ε2 carriers. More than
90% of patients with HLP type III are homozygous ε2/ε2, revealing the
APOE2 isoform to be the major driver of the disease (Utermann et al.,
1977). The APOE2 isoform binds the APOE-receptor with lower affinity,
disturbing hepatic remnant uptake, altering lipolysis of lipoproteins,
and overproducing VLDL. These effects are compounded due to the
increase in APOE levels in ε2 individuals (Mahley et al., 1999). How-
ever, less than 10% of homozygous APOE2 individuals develop hy-
perlipidemia. In fact, most ε2/ε2 subjects are normolipidemic or even
hypolipidemic (Rall et al., 1982; Sing and Davignon, 1985). Therefore,
it appears there are external factors that cause the change to HLP type
III. Among others, the overproduction of apoB or the decrease of LDL
receptors have been reported as secondary factors that lead to the de-
velopment of type III HLP (Chung and Segrest, 1983). Furthermore, it
has been reported that estrogen levels modify the hyperlipidemic pro-
file of the disease. Estrogens increase both LDL receptor expression and
lipolytic activity and as a result, men are more susceptible to HLP type
III than women (Mahley et al., 1999). Together, these studies point to
type III HLP as a multifactorial disease, requiring not only APOE2, but
also genetic, hormonal or environmental factors, such as obesity, hy-
pothyroidism, estrogen status or diabetes (Utermann, 1989).
3.3. Diabetes
Type II diabetes mellitus (T2DM) is one of the most common dis-
eases in humans, with a high incidence and prevalence around the
world (Bommer et al., 2018). CVD is the main cause of morbidity and
mortality among diabetic patients (Rawshani et al., 2018). Insulin re-
sistance and altered function of pancreatic β-cells are the two major
conditions causing T2DM. Insulin resistance implies that insulin does
not exert its function in insulin-sensitive tissues, such as skeletal
muscle, adipose tissue, liver or endothelium. Pancreatic β-cells secrete,
in turn, higher insulin levels to compensate for the reduced action on
peripheral tissues and to maintain glucose levels within a normal range
(Taylor, 1999).
Lipid metabolism plays an important role in this disease. Diabetic
patients present an excess of circulating free fatty acids (FFAs) and TGs,
as well as ectopic lipid storage in muscle and liver (McGarry, 2001).
The association between APOE genotype and insulin resistance has been
widely studied in subjects with or without AD although it still remains
controversial (Elosua et al., 2003; Meigs et al., 2000; Profenno and
Faraone, 2008; Ravona-Springer et al., 2014; Scuteri et al., 2005;
Shinkuro and et al., 1996; Valdez et al., 1995). Some studies found
impaired glucose tolerance in APOE4 individuals (Elosua et al., 2003;
Ravona-Springer et al., 2014; Scuteri et al., 2005; Valdez et al., 1995),
while others did not observe this relationship (Meigs et al., 2000;
Profenno and Faraone, 2008; Shinkuro and et al., 1996). In addition, we
reported that the expression of GLUT 4 in adipocytes correlated posi-
tively with APOE3, but not with APOE4 expression (Arbones-Mainar
et al., 2008). A possible explanation is that APOE4 can reduce insulin-
receptor substrate 1 expression and Akt phosphorylation (Ong et al.,
2014), the latter required for insulin regulation of GLUT4 up-regulation
and translocation (Thong et al., 2005). In contrast, the expression of a
glucose transporter independent of insulin signaling (GLUT1) increased
along with APOE4 expression (Arbones-Mainar et al., 2008). Decreased
expression of GLUT4 with simultaneous increased expression of GLUT1
is conducive to insulin resistance in dystrophic adipose tissues (LaRosa
et al., 2006). This suggests that cells expressing APOE4 have to increase
the expression of GLUT1 in order to maintain glucose transport in the
cell due to the lower response of GLUT4. This insensitivity to insulin
action may have implications for other APOE-associated disorders
where impaired glucose metabolism has been noted, such as AD
(Keeney et al., 2015).
In this background of a T2DM epidemic, several antidiabetic drugs
have been developed over time. A preliminary study in individuals on
metformin and metformin-sulfonilurea combination therapy observed
significantly improved cardiometabolic outcomes (2-h glucose and
systolic blood pressure) in APOE4 non-carriers when compared to
APOE4 carriers (Sapkota et al., 2015). Likewise, evidence suggests that
APOE polymorphisms impact the efficacy of rosiglitazone (a PPARγ
agonist) on cognitive outcomes for AD patients (Iketani et al., 2018;
Risner et al., 2006). However, pharmacogenetics studies have not found
any APOE genetic variant deferentially associated with an antidiabetic
response to the most common antidiabetic drugs [reviewed in
(Mannino et al., 2019)].
3.4. Obesity
According to the World Health Organization (WHO), obesity is de-
fined as an excessive accumulation of fat that can be harmful to health.
In recent years, obesity has become a serious public health problem in
developed countries, increasing the risk of diabetes, dyslipidemia and
hypertension. The crucial role of APOE in this disease has been
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demonstrated in apoE deficient (EKO) mice, which are thinner and
more resistant to obesity than control mice (Chiba et al., 2003; Gao
et al., 2007; Hofmann et al., 2008; Karagiannides et al., 2008). APOE's
effect on body mass may be due to its many roles in adipose tissue
(described above in the “adipose tissue” section). Moreover, a leptin-
sensitizing along with potential direct effects of APOE on neurons have
also been proposed (Gao et al., 2007). In addition to reducing BMI,
APOE deficiency also reduces some of the metabolic complications as-
sociated with obesity, including glucose intolerance and insulin re-
sistance (Gao et al., 2007; Hofmann et al., 2008). As APOE promotes
lipid accumulation, its absence might reduce ectopic fat deposition
insulin sensitive tissues (Hofmann et al., 2008), which is a primary
driver of impaired carbohydrate metabolism (McGarry, 2001).
However, there is some controversy regarding the relationship be-
tween APOE polymorphisms and obesity. While there are studies that
show a strong association between the ε2 allele and the development of
obesity (Duman et al., 2004; Tejedor et al., 2014; Volcik et al., 2006;
Zeljko et al., 2011), others studies do not find any relationship (Zarkesh
et al., 2012; Zhang et al., 2012). This disparity can be explained in part
by the heterogeneity of the populations studied, the low number of
individuals carrying the ε2 allele, and the relationship between APOE
and plasma lipids, which makes it difficult to study the isoforms in
relation to adiposity (Tejedor et al., 2014). In this regard, rodent models
expressing human APOE2 isoform have shown a postprandial accu-
mulation of lipids, increasing adiposity and susceptibility to obesity
induced by diet (Kuhel et al., 2013; Pendse et al., 2009). In addition, an
inflammatory status is promoted, accelerating tissue dysfunction and
increasing infiltration of macrophages (Kuhel et al., 2013). However,
unlike humans, these APOE2 mice develop hyperlipidemia even under
low-fat diet conditions. Therefore, the mechanisms implied in trigly-
ceride-rich lipoprotein metabolism seem to be different in humans
versus mice (Kuhel et al., 2013). Interestingly, elderly women with
APOE4 and AD lost weight while APOE4 non-carriers did not during
3.5 years of follow-up, after controlling for diabetes and exercise
(Vanhanen et al., 2001).
3.5. Metabolic syndrome
Metabolic syndrome (MetS) is a combination of a number of con-
ditions that includes central obesity, elevated blood pressure, hy-
perglycemia and dyslipidemia (Grundy et al., 2004). The strong herit-
ability of these factors suggests that MetS may be regulated by genotype
differences. In fact, previous studies have discovered clusters of genes
related to this syndrome (including APOE) with a heritability of 30%
(Bosy-Westphal et al., 2006).
The relationship between APOE4 and MetS has been evaluated in
several populations and its presence has been considered either neutral
(Lee et al., 2011; Miller et al., 2007; Onat et al., 2010; Teixeira et al.,
2014) or a risk factor for metabolic syndrome (Das et al., 2009; Olivieri
et al., 2007; Tao et al., 2011; Vučinić et al., 2014). However, a pro-
tective function for APOE4 has also been described in a study on grade
III obese individuals, where APOE4 was more frequently found in car-
riers without MetS as compared to subjects suffering from MetS
(Ferreira et al., 2011). These discrepancies might be the result of a
limited number of subjects in the studies due to the low frequency of
the ε2 and ε4 alleles within the population. Additionally, environmental
and social factors can influence these results.
A study conducted by our group showed that the APOE4 isoform
was associated with an increased risk of MetS only in overweight in-
dividuals (Torres-Perez et al., 2016). This relationship was not found in
normal weight or obese subjects. This BMI-dependent effect might be
explained because individuals with lower body mass index (BMI) may
still overcome this adipose dysfunction while in obese subjects the mild
increase of the MetS risk caused by carrying the ε4 allele would appear
masked by the dramatic effect that an excessive expansion of the adi-
pose tissue per se has on increasing the risk of developing MetS.
3.6. Alzheimer's disease
While this review has so far focused on the peripheral functions of
APOE, there exist many parallels between the functions of APOE in the
periphery and its functions in the CNS. This can be particularly ap-
preciated in AD, where 60–80% of patients have at least one ε4 allele
(Mayeux et al., 1998). AD is the most prevalent neurodegenerative
disease, characterized by synapse loss and neuronal death (Hashimoto
et al., 2003). Major hallmarks of the disease include deposition of
amyloid β peptide into extracellular plaques, aggregation of hyper-
phosphorylated tau protein in neurofibrillary tangles, widespread
neuroinflammation, and disruption of the blood-brain-barrier (BBB)
(Wisniewski et al., 1997). APOE4 is the strongest genetic risk factor for
late-onset sporadic AD (Mayeux et al., 1998) and has been implicated in
each of these major hallmarks of the disease. In the context of the
present review, we will briefly highlight that the role of APOE in AD is
not limited solely to the CNS, but also manifests in the periphery.
The majority of APOE research in AD has focused on how the var-
ious isoforms interact with the amyloid pathway that regulates the
synthesis and clearance of the amyloid β peptide (Aβ). Mechanisms
implied in this neuronal dysfunction appear to be mainly two-fold: i) ε4
accelerates Aβ deposition in cholesterol-rich lipid rafts and ii) ε4 alters
APOE receptor signaling to diminish protection against amyloid accu-
mulation (Lane-Donovan and Herz, 2017). However, APOE also effects
handling of Aβ in the periphery. Human ε4 targeted replacement mice
injected with synthetic human Aβ42 cleared it more slowly from the
plasma than ε2 or ε3 mice (Sharman et al., 2010).
A similar parallel between the periphery and CNS is seen with
APOE's effects on tau. In the CNS, APOE4 stimulates tau phosphoryla-
tion, leading to cytoskeletal disruption (Holtzman et al., 2000). How-
ever, APOE may also act upon tau in the periphery. It has been shown
that young healthy APOE4 individuals had more phosphorylated tau in
circulating peripheral lymphocytes than their APOE3 counterparts,
which was associated with subjective cognitive impairment (Badia
et al., 2013).
Inflammation is another major hallmark of AD. APOE4 is associated
with increased proinflammatory cytokine production in the CNS [re-
viewed in (Fernandez et al., 2019)] and is intricately linked to the
dysfunctional microglial phenotype prevalent in AD (Krasemann et al.,
2017). Likewise, APOE4 is also associated with an increased in-
flammatory response in the periphery. For example, APOE4 carriers
undergoing cardiopulmonary bypass surgery had increased proin-
flammatory IL8 and TNFα (Grocott et al., 2001), while the ε4 allele was
associated with a lower antiinflammatory IL-10 serum levels in patients
with coronary artery disease (Tziakas et al., 2006).
Lastly, it has been shown that APOE regulates the blood-brain
barrier (BBB) integrity and that this regulation is isoform-dependent
(Chernick et al., 2019). Peripheral APOE4 compromised the BBB in-
tegrity in some studies, but not all, in mice expressing human APOE
isoforms [reviewed in (Yamazaki et al., 2019)]. Thus, the role of APOE
in AD is clearly multifactorial, impinging upon not only the amyloid
cascade hypothesis but also many of the other major hallmarks of the
disease. Importantly, it is becoming clear that both peripheral and
central APOE share the task of maintaining neurological health.
3.7. Fertility
Yet another site of APOE action is in the endometrium, which
produces APOE and dramatically upregulates its mRNA during the
implantation window (Kao et al., 2002). In addition, APOE is the major
supplier of the cholesterol precursor required for estrogen and proges-
terone synthesis in steroids tissues (Gwynne and Strauss III, 1982). It
has therefore been suggested that APOE might influence human ferti-
lity. In this regard, female ε4 carriers have higher progesterone levels,
implying higher fertility (Jasienska et al., 2015). Some studies have
tried to measure the reproductive efficiency inferred by quantifying the
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offspring. This method may encounter some confounding factors, such
as the use of contraceptive methods, the difficulty of covering the
complete reproductive history of the subjects, and that the number of
biological children in the case of men may be inaccurate. For this
reason, these studies are usually carried out in subjects with advanced
age or in pre-industrial populations in which the offspring is considered
to correspond to reproductive efficiency. In this sense, the studies seem
to point out that in the populations of Caucasian origin, the carriers of
APOE3 have the greatest fertile potential (Corbo et al., 2004a; Corbo
et al., 2007; Gerdes et al., 1996), while APOE4 carriers present greater
reproductive efficiency in populations with Afro-Ecuadorian origins
and in the Cayapa Indians (Corbo et al., 2004b). Interestingly, in all
populations, the allele with the worst reproductive efficiency seems to
be ε2 (Corbo et al., 2004a, 2004b). However, we must be careful when
drawing conclusions due to the previously mentioned confounding
factors. It is worth noting that parity was found to be associated with a
significantly lower AD onset age than nulliparity in APOE3/E3 and
APOE2/E3 individuals, but not in women with APOE4 (Corbo et al.,
2007).
Setarehbadi et al also reported a differential distribution of APOE
genotype related to male fertility (Setarehbadi et al., 2012). However,
in contrast to the studies mentioned above, they associated male APOE4
carriers with a higher risk for infertility. They suggest that differences
between the spermatozoa lipid composition according to APOE allele
affect sperm viability. The population studied and the environmental
factors, among others, may explain the discrepancies observed (Corbo
et al., 2004b). In this regard we have observed that, when women's race
was considered, no effect of APOE isoforms on miscarriage risk was
observed for black women. Interestingly we did detect increased odds
for miscarrying in white pregnant women bearing APOE2 (Gamundi-
Segura et al., 2016). This race-dependent effect may reconcile, at least
partially, the conflicting reports of the association of APOE poly-
morphisms and fertility.
3.8. Longevity and aging
APOE is among the most studied genes associated with longevity. A
pioneering study reported a cohort of centenarians enriched of ε2 al-
leles (Schächter et al., 1994). Thus, APOE2 has been associated with the
lowest fertility but also the highest longevity (Fig. 2). This phenomenon
indicates a potential antagonistic pleiotropy and may explain the per-
sistence of the ancestral ε4 allele, despite its indication in greater dis-
ease risk, as a sort of longevity-fertility trade-off (Corbo et al., 2004a;
Jasienska et al., 2015).
Some genome-wide association studies (GWAS), but not all, have
tied the ε4 allele of APOE to shortened longevity due to its role in
multiple age-related diseases, whereas the ε2 allele is linked to in-
creased longevity, mainly by its protective role against CVD and AD.
Thus, APOE is an important player in aging and a major determinant of
longevity (Ryu et al., 2016).
3.9. Infectious diseases
Cholesterol is essential for human immunodeficiency virus (HIV)
entry and assembly (Liao et al., 2003; Mañes et al., 2000). Due to the
influence of APOE in cholesterol transport, a correlation between HIV
infection and APOE has been suggested. HIV infection may resemble an
inflammation status akin to accelerated aging. Additionally, HIV re-
plication in the brain is associated with several neurological disorders,
including dementia. Therefore, APOE4 has been studied as a risk
marker of HIV-associated neurocognitive disorders (Geffin and
McCarthy, 2018). Nevertheless, this correlation has not been found in
all APOE4 carriers. Becker et al suggested an age differential effect of ε4
allele in HIV patients, with elderly patients being more susceptible to
neurocognitive decline (Becker et al., 2015). In concordance with this
hypothesis, several studies point to an aging accelerated effect in brain
HIV-infected APOE4 carriers through the interaction between HIV
proteins and APOE4, increasing Αβ production and neurotoxicity to
infected cells (Chang et al., 2014; Tuminello and Han, 2011; Wendelken
et al., 2016).
Hepatitis C virus (HCV) associates with lipoproteins being secreted
from the liver as highly infective lipoviro particles (LVP). Interestingly,
APOE plays a relevant role in the assembly and production of these
LVPs (Weller et al., 2017). The importance of this apolipoprotein is
evidenced by the fact that APOE depletion has a significant effect in
HCV particle production compared to APOB or APOA1 depletion
(Benga et al., 2010). In this sense, some epidemiological studies have
reported that APOE4 was associated with a reduced likelihood of HCV
chronic infection (Mueller et al., 2016; Price et al., 2006). However,
mixed results such as the fact that APOE4 was also associated with
better histologic outcomes in recurrent HCV infection (Toniutto et al.,
2004), no effect on the anti-viral response (Kim et al., 2013), or poor
treatment response in HCV G1b patients (Mueller et al., 2003), have
likely precluded the use of APOE genotypes as biomarker in the mor-
bidity of chronic HCV infection. Those discrepant results may reflect
the limited sample size included in some studies and the failure to ex-
amine the interaction of APOE genotypes-HCV genotypes and its
modulation by HCV treatments
APOE4 increases oxidative damage in the CNS and intensifies
herpes simplex virus (HSV) latency (Kuhlmann et al., 2010). HSV-1 and
APOE also compete to bind the same LDL receptor. HSV-1 has been
detected in brain regions affected by AD, demonstrating its influence in
β-amyloid production and accumulation. Burgos et al reported that the
ε4 allele is more permissive to the migration of HSV-1 from the adrenal
gland to the brain (Burgos et al., 2006). They also showed higher latent
HSV-1 DNA levels in ε4 carriers. Thus, it is suggested that susceptibility
for HSV-1 is increased by the presence of ε4 allele. Furthermore, the
combination of HSV-1 and APOE4 may increase the propensity to de-
velop AD (Kuhlmann et al., 2010). It is hypothesized that higher LDL
levels produced by ε4 carriers promote accumulation of cholesterol in
lipid rafts, facilitating the entry and latency of the herpes virus (Burt
et al., 2008).
4. Discussion
While the spectrum of biological systems in which APOE plays a role
seems implausibly wide at first glance, there are some potential uni-
fying mechanisms that could tie these seemingly disparate disorders
together. Although liver transplantation studies have demonstrated that
peripheral and brain APOE represent two distinct pools that are not
Fig. 2. Antagonistic pleiotropy in APOE genotypes. APOE4 individuals enjoy
enhanced fertility at the expense of longevity, whereas APOE2 individuals have
increased longevity but reduced fertility.
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exchangeable (Linton et al., 1991), APOE need not cross the blood brain
barrier for its influence on the periphery to also be felt in the brain.
Alterations to lipid trafficking, cellular metabolism, and immune
function overlap and may act synergistically on both sides of this bar-
rier to promote APOE's widespread effects in the tissues, systems and
disorders described in this review.
Cholesterol is the main constituent of many structural tissues in the
periphery and is also critical in supporting the function of the brain, an
organ which represents approximately 2% of total body weight yet
contains as much as 25% of total cholesterol (Dietschy and Turley,
2001). As APOE is an important regulator of cholesterol transport and
metabolism, alterations resulting from APOE isoform-specific differ-
ences have the capacity to produce greater impact, playing a role in
multiple prevalent diseases. For example, the role of APOE in mod-
ulating LDL cholesterol levels in the background of CVD is well docu-
mented, and APOE isoform specific changes in glial cholesterol meta-
bolism implicate these pathways in AD risk (Fernandez et al., 2019).
Understanding the mechanisms by which APOE influences cholesterol
homeostasis to confer disease risk will help to develop effective thera-
pies for a wide range of maladies.
Although several of the molecular mechanisms through which
APOE exerts its effects have been elucidated through studies in rodent
models, often times contradictory results have been obtained according
to the animal model studied. Human studies have reported yet even
greater differences. APOE effects typically vary by age, often being
more detrimental in elderly than in younger populations. For example,
the magnitude of the associations between APOE genotype and plasma
lipid levels differ according to sex and the population studied
(Rasmussen, 2016). Results are further obfuscated by the complicated
effect of different dosage levels of APOE alleles (Cacciaglia et al., 2018).
APOE-specific alterations in energy homeostasis and/or mitochon-
drial function are another potential area in which a single APOE iso-
form directed change could drive pathological changes in multiple
disorders both centrally and in the periphery. The notion that APOE
isoforms differentially mediate cell bioenergetics is gaining momentum
as new findings challenge old assumptions (Kuehn, 2020). Along these
lines, our group has shown that mice expressing human APOE4 have a
global metabolic shift toward lipid oxidation and are inherently in-
efficient at utilizing glucose (Arbones-Mainar et al., 2016). This im-
paired glucose metabolism has implications for a number of disease
states in which APOE plays a role. Mainly in the MetS and diabetes, as
both conditions have defective glucose metabolism as their underlying
cause, but also in CVD and in AD (Fig. 3). The latter is characterized by
a pattern of cerebral glucose hypometabolism, likely related to early
mitochondrial dysfunction. This pattern is closely reflected in the brains
of even young, cognitively normal individuals with APOE4 (Fukai et al.,
2018). Mitochondria are essential for the regulation of the metabolic
switch between lipids and glucose to fuel cellular functions. Some
evidence points toward mitochondrial dysfunction as a primary event
in AD onset (Weidling and Swerdlow, 2019). In this regard, APOE4
uniquely can be cleaved by a neuron-specific protease, resulting in toxic
fragments of APOE4(1–272), that can bind mitochondrial complexes
and disrupt mitochondrial energy balance (Nakamura et al., 2009).
Alternatively, some studies propose a “systemic” mitochondrial dys-
function status as the trigger of a number of neurodegenerative and
metabolic diseases such as T2DM, CVD, and AD (Bhatti et al., 2017).
Inflammatory responses are critical for an organism's ability to re-
spond to and eliminate pathogens, but widespread inflammation is also
seen in the brain undergoing neurodegeneration. APOE drives in-
flammatory microglial phenotypes in AD, where isoform differences
profoundly influence the production of inflammatory cytokines and the
capacity of microglia to respond to and clear amyloid plaques and
neuronal debris. Peripheral inflammatory responses are also modulated
by APOE genotype, as is the case for disparate infections ranging from
HIV to HCV to HSV. Furthermore, inflammation in the two compart-
ments may interact. Peripheral inflammation damaged the integrity of
the blood brain barrier in an AD mouse model with targeted replace-
ment human APOE4, promoting cerebrovascular leakiness and reduced
cerebral vessel coverage (Marottoli et al., 2017). Thus, APOE's gen-
eralized effects on immune system function present a strong candidate
for tying together the deleterious isoform-dependent differences seen in
otherwise distinct pathologies and in distinct body compartments.
In summary, the effects of APOE across human biology are nu-
merous and diverse. This critical protein has been shown to play a role
in biological systems ranging from adipose tissue function and fertility
to infection to neurological disease. Despite this diversity, there appear
to be shared pathways that may provide insight into a unifying me-
chanism of action. While much remains to be discovered about this
pleiotropic protein, research over the past 45 years has provided im-
portant insight into potential therapeutic targets that could have ben-
efits across a wide range of disorders.
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